THURSDAY, SEPTEMBER 3, 2026

SATELLITE SYMPOSIUM
THURSDAY, SEPTEMBER 3, 2026, 11.35 am – 12.35 pm
Detect the Mutation – Molecular Profiling and Therapeutic Consequences in Metastatic Breast Cancer
Chair:  S. Kümmel
Welcome & Introduction
S. Kümmel
Beyond the Tissue - Mastering ESR1-mutations with Liquid Biopsy
M. Graf
Guideline Recommendations and Implementation in Clinical Practice
A.-K. Bittner
What‘s Coming Soon & Plenum Discussion
S. Kümmel, M. Graf, A.-K. Bittner
With the kind support of
Menarini Stemline Deutschland GmbH
SATELLITE SYMPOSIUM
THURSDAY, SEPTEMBER 3, 2025, 02.30 - 03.30 pm
From Trial to Treatment – New Therapeutic Approaches and Practical Implementation in Breast Cancer and Gynaecological Tumors
Chair:  S. Kümmel
HR+, HER2-Metastatic Breast Cancer
S. Gipe
Discussion
S. Kümmel, S. Gipe
Chair:  P. Harter
From DNA-Damage Response to HER2-Expression: Biomarkers Guiding Treatment in Endometrial and Ovarian Cancer
B. Ataseven
Discussion
P. Harter, B. Ataseven
With the kind support of
AstraZeneca GmbH

FRIDAY, SEPTEMBER 4, 2026

SATELLITE SYMPOSIUM
FRIDAY, SEPTEMBER 4, 2026, 12.40 - 01.40 pm
A Patient-Centered Journey: Individualized Treatment Options in Ovarian Cancer
Chair:  P. Harter
Welcome and Introduction
P. Harter
Defining the First Steps: Role of Surgery, Testing and Individualized Therapy at Primary Diagnosis and Platinum-Eligible Relapse
S. Mahner
Classical Single Agent Chemotherapy will be Outdated soon: Era of New Options has Arrived in PROC
L. Hanker
When Time Matters Most: Balancing Efficacy, Quality of Life and Time Toxicity in Platinum-Resistant Ovarian Cancer
F. Hilpert
Panel Discussion
L. Hanker, F. Hilpert, P. Harter, S. Mahner
With the kind support of
AbbVie Deutschland GmbH & Co. KG
SATELLITE SYMPOSIUM
FRIDAY, SEPTEMBER 4, 2026, 03.30 – 04.30 pm
Breaking Through Resistance: New and Evolving Treatment Strategies in Platinum-Resistant Ovarian Cancer
Chair:  P. Harter
Welcome and Introduction
P. Harter
Where Are We Now? The Current Treatment Landscape and Unment Needs in PROC
P. Harter
Shifting the Paradigm in PROC: Emerging Pathways and Expanding Options
F. Marmé
Targeting Glucocorticoid Receptor-Driven Resistance: Emerging Evidence and Clinical Relevance
D. Lorusso
Panel Discussion & Audience Q&A
P. Harter, F. Marmé, D. Lorusso
With the kind support of
Corcept Therapeutics Incorporated

SATURDAY, SEPTEMBER 5, 2026

SATELLITE SYMPOSIUM
SATURDAY, SEPTEMBER 5, 2026, 08.45 – 09.30 am
Chair:  P. Harter
Welcome
P. Harter
High-Risk Early Breast Cancer: Tailoring Treatment Intensification to Patient Risk
S. Kümmel
Recurrent Ovarian Cancer: Evolving Treatment Strategies and Clinical Challenges
J. Sehouli
Discussion
With the kind support of
Lilly Deutschland GmbH
SCIENTIFIC SYMPOSIUM
SATURDAY, SEPTEMBER 5, 2026, 11.40 am -12.40 pm
Transforming Treatment from First Line to Early Stage
Chair:  S. Kümmel
Redefining First-Line Standards with Established ADCs in mBC
M. Thill
Unlocking New Curative Potential in HER2+ eBC
N. Harbeck
With the kind support of
Daiichi Sankyo Deutschland GmbH